Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,380 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- OncoTree
- PROSTATE
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,984 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03949517 | 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy | completed | Phase 1 / Phase 2 | 14 | Andrei IagaruOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT04176081 | Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer(SChLAP/IDC) | not yet recruiting | Phase 2 | 208 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 |
| clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01704274 | GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy(GTN) | completed | Phase 2 | 43 | Dr. D. Robert SiemensOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03809078 | 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer | completed | Phase 2 | 14 | Andrei IagaruOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT00176631 | Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT00633087 | A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer(2-Deoxyglucose) | terminated | Phase 1 / Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03837353 | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | terminated | Phase 1 / Phase 2 | 18 | NYU Langone HealthOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC(ANZUP2001) | unknown | Phase 2 | 93 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04242017 | Long-term Better Than Short-term ADT With Salvage RT(LOBSTER) | recruiting | Phase 2 / Phase 3 | 394 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03113617 | 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer | completed | Phase 2 | 44 | Andrei IagaruOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06029036 | A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer | unknown | Phase 2 | 53 | Peking University First HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT00915122 | Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate | completed | Phase 1 / Phase 2 | 81 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT00818623 | Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients | completed | Phase 2 | 172 | Ferring PharmaceuticalsINDUSTRY | 7 | Nov 30, 2023 | clinicaltrials |
| NCT00819156 | Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer | completed | Phase 2 | 189 | Ferring PharmaceuticalsINDUSTRY | 8 | Nov 30, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03459820 | Prostate Cancer Patient Management With 18F-DCFPyL PET/CT | enrolling by invitation | Phase 2 / Phase 3 | 1,500 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT00584532 | Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.(GCP) | completed | Phase 2 / Phase 3 | 66 | University of California, DavisOTHER | 0 | Nov 24, 2023 | clinicaltrials |
| NCT03513211 | Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer(HITMAN-PC) | completed | Phase 1 / Phase 2 | 12 | St Vincent's Hospital, SydneyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01972217 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | completed | Phase 2 | 158 | AstraZenecaINDUSTRY | 11 | Nov 14, 2023 | clinicaltrials |
| NCT06129851 | Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | not yet recruiting | Phase 2 | 90 | University of Kansas Medical CenterOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00819247 | The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer | completed | Phase 2 | 129 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT00587431 | Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer | completed | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03396874 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | completed | Phase 2 | 1,435 | University of MichiganOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT00337155 | BAY88-8223, Dose Finding Study in Patients With HRPC | completed | Phase 2 | 122 | BayerINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT00020046 | Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | terminated | Phase 2 | 10 | University of WashingtonOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT01956058 | Brachytherapy for Recurrent Prostate Cancer(CAPRICUR) | completed | Phase 2 | 30 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03830164 | Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT01420861 | GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer | terminated | Phase 2 | 18 | GTxINDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05555017 | Tracer-Guided Surgery for Recurrent Prostate Cancer(Trace-II) | unknown | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT00736645 | Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 55 | Roswell Park Cancer InstituteOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT01377389 | Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | terminated | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT01867333 | Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 80 | Veru Inc.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05613842 | Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)(BOP) | completed | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01607879 | Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation | completed | Phase 2 | 48 | Medical College of WisconsinOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05516329 | Study of 18F-Thretide PET/CT in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT00176644 | Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00483561 | Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 26 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01558427 | Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer | completed | Phase 2 | 62 | University Hospital, GhentOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT04614363 | 68 Ga-PSMA for High Risk Prostate Cancer | completed | Phase 1 / Phase 2 | 80 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT06006104 | Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 49 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Aug 23, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Jan 30, 2024source: clinicaltrials